BM-L13

BM-L13 is an investigational drug candidate being developed by Beimei Pharmaceutical (also known as Bainei Pharmaceutical) for the treatment of hemorrhagic disease in neonates. Currently in the IND-enabling (Pre-IND) stage, BM-L13 is part of a specialized pediatric pipeline focused on addressing unmet medical needs in infants and children. Although the specific active ingredient and mechanism of action have not been publicly revealed, the drug's target indication suggests it may involve the regulation of blood coagulation or the supplementation of essential factors like vitamin K to prevent or treat bleeding disorders in newborns, such as vitamin K deficiency bleeding (VKDB).